Every 8-K that Sionna Therapeutics, Inc. (SION) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SION and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SION filings page.
Sionna Therapeutics, Inc. (SION) approved a major restructuring to concentrate resources on its SION-451 and SION-2222 dual combination cystic fibrosis program and to extend its cash runway. The plan includes reducing the workforce by approximately 46% and winding down the SION-719 add-on program, including related clinical and manufacturing contracts.
Sionna estimates approximately $6.4 million in restructuring and related charges, primarily severance and contract close-out costs, with activities largely completed by the end of the third quarter of 2026 and cash payments continuing into the fourth quarter of 2026. The Chief Business Officer, Caroline Stark Beer, will depart effective September 15, 2026, and existing executives will assume expanded roles without compensation changes. The Board also approved a stock option repricing effective September 17, 2026, lowering exercise prices of certain employee options to the stock’s closing price on the repricing date, subject to an 18‑month retention period. Sionna plans to initiate the AscenSION CF Phase 2a proof‑of‑concept trial of SION-451 + SION-2222 in the first quarter of 2027 and, based on its cash of $268.3 million at the end of Q2 2026 and cost-saving measures, estimates its cash runway extends into the second half of 2029.
Sionna Therapeutics, Inc. reported topline results from two cystic fibrosis programs and outlined strategic changes. The Phase 2a PreciSION CF proof-of-concept trial of SION-719, added to Trikafta in people with cystic fibrosis, did not achieve the key activity endpoint of sweat chloride reduction, and the company is not advancing SION-719 as an add-on to standard of care. Potential confounders in this trial are being evaluated to guide next steps for the SION-451 dual combination program, which has completed a Phase 1 healthy volunteer trial with dual combinations involving SION-2222 and SION-109. Sionna ended Q2 with approximately $268.3 million in cash, cash equivalents, and marketable securities and plans to take actions to preserve capital while assessing future development plans.
Sionna Therapeutics, Inc. reported second quarter 2026 results and provided an update on its cystic fibrosis pipeline. Research and development expenses were $21.9 million and general and administrative expenses were $10.6 million, resulting in a net loss of $29.9 million, or $0.66 per share for the quarter.
The company reported $268.3 million in cash, cash equivalents and marketable securities as of June 30, 2026 and expects this cash position to fund operations into 2028. Pipeline highlights include the PreciSION CF Phase 2a proof-of-concept trial of NBD1 stabilizer SION-719 as an add-on to standard of care and a Phase 1 dual combination trial of SION-451 with SION-2222 and SION-109, both on track for topline data in summer 2026. Sionna also presented encore clinical and nonclinical data on its NBD1 stabilizers at major cystic fibrosis conferences.
Sionna Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on June 17, 2026. Stockholders voted on the election of four Class II director nominees and the ratification of the company’s independent registered public accounting firm.
All four Class II director nominees—H. Edward Fleming, Jr., M.D., Marcella Kuhlman Ruddy, M.D., Peter A. Thompson, M.D., and Joanne Louise Viney, Ph.D.—were elected to serve until the 2029 annual meeting. Stockholders also ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
There were 45,142,330 shares of common stock outstanding as of the April 21, 2026 record date, and a quorum was present at the meeting, allowing these proposals to be approved.
Sionna Therapeutics, Inc. reported first quarter 2026 results and a business update focused on its cystic fibrosis pipeline. The company completed enrollment in its PreciSION CF Phase 2a proof‑of‑concept trial of NBD1 stabilizer SION-719 as an add-on to standard of care, with topline data expected in summer 2026. An ongoing Phase 1 trial of NBD1 stabilizer SION-451 in dual combinations with SION-2222 and SION-109 is also on track for topline data in the summer.
Research and development expenses were $19.0 million and general and administrative expenses were $10.6 million for the quarter, leading to a net loss of $26.8 million, or $0.60 per share. Sionna ended March 31, 2026 with $289.9 million in cash, cash equivalents and marketable securities, which it expects to fund operations into 2028.
Sionna Therapeutics reported fourth quarter and full year 2025 results, highlighting progress in its cystic fibrosis pipeline and a strengthened balance sheet. The company recorded a net loss of $20.4 million for the quarter and $75.3 million for the year ended December 31, 2025.
Research and development expenses were $15.2 million in the quarter and $60.3 million for the year, while general and administrative expenses reached $8.4 million and $28.7 million, respectively, reflecting expanded operations after its upsized IPO. Cash, cash equivalents and marketable securities totaled $310.3 million at year-end, which Sionna expects will fund operations into 2028.
The company is running a Phase 2a proof-of-concept trial of NBD1 stabilizer SION-719 as an add-on to standard of care in cystic fibrosis, and a Phase 1 dual combination trial of SION-451 with complementary CFTR modulators, with topline data from both trials anticipated in mid-2026.
Sionna Therapeutics, Inc. furnished an update on its latest performance by submitting an 8-K that includes a press release with financial results and business highlights for the quarter ended September 30, 2025. The company describes these quarterly results and operational developments in the press release attached as Exhibit 99.1 to the report.
Sionna Therapeutics furnished a press release announcing its financial results and business highlights for the quarter ended June 30, 2025. The Form 8-K states the full text of that press release is furnished as Exhibit 99.1 to the Current Report and clarifies that the information is furnished, not filed, so it is not subject to Section 18 liabilities or incorporated by reference in other filings unless expressly stated. The filing also confirms the company’s Delaware incorporation and Nasdaq listing under the ticker SION, and indicates the company qualifies as an emerging growth company. Investors should consult Exhibit 99.1 for the actual financial figures and business highlights.